BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 12742959)

  • 1. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ: a more aggressive disease?
    Zunzunegui RG; Chung MA; Oruwari J; Golding D; Marchant DJ; Cady B
    Arch Surg; 2003 May; 138(5):537-40. PubMed ID: 12742959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
    Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
    Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma.
    Tabar L; Tony Chen HH; Amy Yen MF; Tot T; Tung TH; Chen LS; Chiu YH; Duffy SW; Smith RA
    Cancer; 2004 Oct; 101(8):1745-59. PubMed ID: 15386334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic analysis of a large series of microinvasive breast cancers.
    Lillemoe TJ; Tsai ML; Swenson KK; Susnik B; Krueger J; Harris K; Rueth N; Grimm E; Leach JW
    Breast J; 2018 Jul; 24(4):574-579. PubMed ID: 29476574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
    Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
    Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
    Curigliano G; Criscitiello C
    J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.
    Dillon MF; McDermott EW; Quinn CM; O'Doherty A; O'Higgins N; Hill AD
    J Surg Oncol; 2006 Jun; 93(7):559-63. PubMed ID: 16705731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microinvasive breast carcinoma: An analysis from ten Senonetwork Italia breast centres.
    Costarelli L; Cianchetti E; Corsi F; Friedman D; Ghilli M; Lacaria M; Menghini L; Murgo R; Ponti A; Rinaldi S; Del Turco MR; Taffurelli M; Tinterri C; Tomatis M; Fortunato L
    Eur J Surg Oncol; 2019 Feb; 45(2):147-152. PubMed ID: 30482543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.
    Han JS; Molberg KH; Sarode V
    Breast J; 2011; 17(3):223-9. PubMed ID: 21545433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida.
    Camp R; Feezor R; Kasraeian A; Cendan J; Schell S; Wilkinson E; Copeland E; Lind S
    Breast J; 2005; 11(6):394-7. PubMed ID: 16297082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics.
    Gajdos C; Tartter PI; Bleiweiss IJ; Hermann G; de Csepel J; Estabrook A; Rademaker AW
    Ann Surg; 2002 Feb; 235(2):246-51. PubMed ID: 11807365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factor for axillary lymph node metastases in microinvasive breast cancer.
    Ko BS; Lim WS; Kim HJ; Yu JH; Lee JW; Kwan SB; Lee YM; Son BH; Gong GY; Ahn SH
    Ann Surg Oncol; 2012 Jan; 19(1):212-6. PubMed ID: 21633867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.
    Yen TW; Hunt KK; Ross MI; Mirza NQ; Babiera GV; Meric-Bernstam F; Singletary SE; Symmans WF; Giordano SH; Feig BW; Ames FC; Kuerer HM
    J Am Coll Surg; 2005 Apr; 200(4):516-26. PubMed ID: 15804465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.
    Parikh P; Pockaj B; Wasif N; Halyard M; Wong W; Kosiorek HE; Dueck AC; Gray R
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S516-21. PubMed ID: 25986869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy.
    Catteau X; Simon P; Noël JC
    Pathol Res Pract; 2012 Apr; 208(4):217-20. PubMed ID: 22445178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.
    Guillot E; Vaysse C; Goetgeluck J; Falcou MC; Couturaud B; Fitoussi A; Fourchotte V; Laki F; Malhaire C; Sigal-Zafrani B; Sastre-Garau X; Bollet MA; Mosseri V; Reyal F
    Breast; 2014 Apr; 23(2):97-103. PubMed ID: 24388733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
    Hwang RF; Gonzalez-Angulo AM; Yi M; Buchholz TA; Meric-Bernstam F; Kuerer HM; Babiera GV; Tereffe W; Liu DD; Hunt KK
    Cancer; 2007 Aug; 110(4):723-30. PubMed ID: 17587208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Tunon-de-Lara C; Giard S; Buttarelli M; Blanchot J; Classe JM; Baron M; Monnier B; Houvenaeghel G
    Breast J; 2008; 14(2):135-40. PubMed ID: 18315691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.